패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Global Blood Therapeutics, Inc. 27 애널리스트 중 18 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jason Matthew Gerberry	BofA Global Research
John Newman	Canaccord Genuity
Elemer Piros	Cantor Fitzgerald & Co.

Global Blood Therapeutics 대차 대조표 상태

재무 상태 기준 확인 2/6

주요 정보

최근 재무 상태 업데이트

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Recent updates

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Executive Vice President of Operations exercised options to buy US$2.0m worth of stock.

Global Blood Therapeutics expects to complete Pfizer deal in early October

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Price target increased to US$66.03

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

CFO & Principal Accounting Officer exercised options and sold US$69k worth of stock

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Independent Director notifies of intention to sell stock

Global Blood Therapeutics: Powerhouse Of The Future

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Blood Therapeutics: Hitting A Growth Inflection

Chief Commercial Officer exercised options and sold US$54k worth of stock

No longer forecast to breakeven

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Consensus EPS estimates fall by 23%

Full year 2021 earnings: EPS exceeds analyst expectations

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Global Blood Therapeutics: Revisiting A Stellar Grower

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Chief Commercial Officer exercised options and sold US$57k worth of stock

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

President exercised options and sold US$140k worth of stock

Global Blood Therapeutics: Attempting To Classify The Investment

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

CFO & Principal Accounting Officer exercised options and sold US$119k worth of stock

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Independent Director exercised options and sold US$59k worth of stock

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics announces employment inducement grants

Consensus EPS estimates fall to -US$4.55

Global Blood Therapeutics: Increasing Specialization In SCD

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Chief Commercial Officer exercised options and sold US$64k worth of stock

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director